U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT07476326) titled 'Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo(R) as Adjuvant Monotherapy in Participants With Melanoma' on March 12.
Brief Summary: The purpose of this study is to investigate the pharmacokinetics (PK) similarity of Bmab1700 (an intended nivolumab biosimilar), compared with United States (US)-licensed Opdivo, in participants after complete surgical removal of melanoma.
Study Start Date: June 01, 2026
Study Type: INTERVENTIONAL
Condition:
Melanoma
Intervention:
DRUG: Bmab1700
Intravenous infusion.
DRUG: Opdivo
Intravenous infusion.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Biocon Bio...